Long-Term results of RTOG 0236 confirm good primary tumour control and positive five-year survival rates for lung cancer patients who received SBRT

Patients with inoperable, early-stage lung cancer who receive stereotactic body radiation therapy (SBRT) have a five-year survival rate of 40 percent, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting. Such a positive survival rate is encouraging considering that historically conventional RT resulted in poor tumour control for patients with inoperable lung cancer.

Market Wired